Crossmark

Phase I/II Study of Neoadjuvant Chemoradiotherapy Consisting of S-1 and Cisplatin for Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer (OGSG1205)

Crossref DOI link: https://doi.org/10.1245/s10434-024-16845-x

Published Online: 2025-01-15

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shinkai, Masayuki

Imano, Motohiro

Yokokawa, Masaki

Tanaka, Ryo

Matsuyama, Jin

Shimokawa, Toshio

Kawakami, Hisato

Satoh, Taroh

Yasuda, Takushi

Furukawa, Hiroshi
License Information

Text and Data Mining valid from 2025-01-15

Version of Record valid from 2025-01-15
More Information

Article History

Received: 17 September 2024

Accepted: 25 December 2024

First Online: 15 January 2025

Ethical approval

: All procedures were performed in accordance with the ethical standards of the committee on human experimentation and with the guidelines of the Declaration of Helsinki 1964 and later versions. This study was approved by the institutional review and ethics board of each participating hospital and registered in the University Hospital Medical Information Network (UMIN) database (UMIN000008964).

: Informed consent or substitute consent was obtained from all patients included in the study.

Document is current

Any future updates will be listed below